Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
Charlie J NederpeltLeon NaarKatelyn W SylvesterMegan E BarraRussel J RobertsGeorge C VelmahosHaytham M A KaafaraniMartin G RosenthalDavid R KingPublished in: Journal of thrombosis and haemostasis : JTH (2020)
We report poor overall outcomes, a low rate of hemostatic effectiveness, and a high rate of ischemic complications and mortality in this retrospective analysis of oral FXa inhibitor reversal with andexanet alfa for extracranial bleeds. More rigorous epidemiological, and ideally randomized studies, are needed to determine the role of andexanet alfa for FXa inhibitor-associated bleeding for extracranial hemorrhages, where large variation in severity and presentation exists.